drugset / Trial / NCT05108545

A Study of Amphotericin B Liposome for Injection in Patients With Persistent Neutropenia and Fever

NCT05108545

NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open-label, single-arm, phase III study to evaluate the safety and efficacy of Amphotericin B liposomes in patients with persistent neutropenia and fever.

Timeline

Start
2021-12-15
Primary completion
2022-07-31
Completion
2023-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Amphotericin B Unknown 3 mg/kg Intravenous

Indications